{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:35:47Z","timestamp":1790390147266,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.kint.2023.06.024","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T18:15:52Z","timestamp":1688408152000},"page":"754-768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Proprotein convertase subtilisin\/kexin type 9 targets megalin in the kidney proximal tubule and aggravates proteinuria in nephrotic syndrome"],"prefix":"10.1016","volume":"104","author":[{"given":"Cecilie K.","family":"Skeby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Hummelgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Gustafsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine P.","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilde","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ivarsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peder","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik I.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3715-7266","authenticated-orcid":false,"given":"Henrik","family":"Birn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Glerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-7987","authenticated-orcid":false,"given":"Kathrin","family":"Weyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2023.06.024_bib1","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2023.06.024_bib2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/01.mnh.0000247496.54882.3f","article-title":"Update on microalbuminuria as a biomarker in renal and cardiovascular disease","volume":"15","author":"Lambers Heerspink","year":"2006","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2023.06.024_bib3","first-page":"CD005425","article-title":"Lipid-lowering agents for nephrotic syndrome","volume":"12","author":"Kong","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2023.06.024_bib4","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.1993.292","article-title":"The increased risk of coronary heart disease associated with nephrotic syndrome","volume":"44","author":"Ordo\u00f1ez","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.06.024_bib5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2023.06.024_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","article-title":"Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences","volume":"90","author":"Vaziri","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.06.024_bib7","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1046\/j.1523-1755.1999.00773.x","article-title":"Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency","volume":"56","author":"Culleton","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.06.024_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/kisup.2013.28","article-title":"Foreword","volume":"3","year":"2013","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.kint.2023.06.024_bib9","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"Pcsk9","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2023.06.024_bib10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.06.024_bib11","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2023.06.024_bib12","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.06.024_bib13","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2023.06.024_bib14","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.06.024_bib15","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1194\/jlr.M700071-JLR200","article-title":"Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis","volume":"48","author":"Qian","year":"2007","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.kint.2023.06.024_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1194\/jlr.M011445","article-title":"A\u00a0PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in\u00a0vivo","volume":"52","author":"Ni","year":"2011","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.kint.2023.06.024_bib17","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A\u00a0proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.06.024_bib18","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.06.024_bib19","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.06.024_bib20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2023.06.024_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.115.020912","article-title":"The role of proprotein convertase subtilisin\/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia","volume":"134","author":"Haas","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2023.06.024_bib22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.atherosclerosis.2012.11.009","article-title":"Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment","volume":"226","author":"Kwakernaak","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.kint.2023.06.024_bib23","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1053\/j.ajkd.2013.10.042","article-title":"Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study","volume":"63","author":"Jin","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.06.024_bib24","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.kint.2020.06.045","article-title":"Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome","volume":"98","author":"Molina-Jijon","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.06.024_bib25","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.kint.2021.01.023","article-title":"Proteinuria converts hepatic heparan sulfate to an effective proprotein convertase subtilisin kexin type 9 enzyme binding partner","volume":"99","author":"Shrestha","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.06.024_bib26","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.metabol.2007.05.007","article-title":"Hepatic tissue sterol regulatory element binding protein 2 and low-density lipoprotein receptor in nephrotic syndrome","volume":"56","author":"Kim","year":"2007","journal-title":"Metabolism"},{"key":"10.1016\/j.kint.2023.06.024_bib27","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/ki.1996.388","article-title":"Down-regulation of hepatic LDL receptor expression in experimental nephrosis","volume":"50","author":"Vaziri","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.06.024_bib28","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ndt\/gft439","article-title":"Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome","volume":"29","author":"Liu","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.06.024_bib29","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1046\/j.1523-1755.2003.00911.x","article-title":"Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis","volume":"63","author":"Vaziri","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.06.024_bib30","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2023.06.024_bib31","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.06.024_bib32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12882-017-0644-0","article-title":"Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report","volume":"18","author":"Awanami","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2023.06.024_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ekir.2020.09.046","article-title":"Efficacy and safety of PCSK9 inhibitors in hypercholesterolemia associated with refractory nephrotic syndrome","volume":"6","author":"Jatem","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.06.024_bib34","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/metabo11110760","article-title":"Proteinuria-lowering effects of proprotein convertase subtilisin\/kexin type 9 inhibitors in chronic kidney disease patients: a real-world multicentric study","volume":"11","author":"Mu\u00f1oz Ramos","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.kint.2023.06.024_bib35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000365935","article-title":"Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy","volume":"40","author":"Konarzewski","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2023.06.024_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2013.12.030","article-title":"Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels","volume":"233","author":"Abujrad","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.kint.2023.06.024_bib37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11010-015-2590-0","article-title":"Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure","volume":"411","author":"Sucajtys-Szulc","year":"2016","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.kint.2023.06.024_bib38","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s11255-017-1505-2","article-title":"PCSK9 in chronic kidney disease","volume":"49","author":"Pavlakou","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.kint.2023.06.024_bib39","first-page":"19","article-title":"Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis","volume":"85","author":"Go","year":"2012","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.kint.2023.06.024_bib40","first-page":"223","article-title":"Endocytic receptors in the renal proximal tubule","volume":"27","author":"Christensen","year":"2012","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.kint.2023.06.024_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.kint.2015.11.007","article-title":"Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease","volume":"89","author":"Nielsen","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.06.024_bib42","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1681\/ASN.2010090984","article-title":"Tubular reabsorption of albumin: it\u2019s all about cubilin","volume":"21","author":"Haraldsson","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.06.024_bib43","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1681\/ASN.2010050492","article-title":"Cubilin is essential for albumin reabsorption in the renal proximal tubule","volume":"21","author":"Amsellem","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.06.024_bib44","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.kint.2017.07.024","article-title":"Abolishment of proximal tubule albumin endocytosis does not affect plasma albumin during nephrotic syndrome in mice","volume":"93","author":"Weyer","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.06.024_bib45","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/ki.2013.218","article-title":"Increased lysosomal proteolysis counteracts protein accumulation in the proximal tubule during focal segmental glomerulosclerosis","volume":"84","author":"Nielsen","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.06.024_bib46","doi-asserted-by":"crossref","first-page":"F1053","DOI":"10.1152\/ajprenal.00006.2013","article-title":"Albuminuria induces a proinflammatory and profibrotic response in cortical collecting ducts via the 24p3 receptor","volume":"305","author":"Dizin","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2023.06.024_bib47","doi-asserted-by":"crossref","first-page":"F150","DOI":"10.1152\/ajprenal.00300.2021","article-title":"Proteinuria is accompanied by intratubular complement activation and apical membrane deposition of C3dg and C5b-9 in kidney transplant recipients","volume":"322","author":"Isaksson","year":"2022","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2023.06.024_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13362","article-title":"Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice","volume":"227","author":"Hinrichs","year":"2019","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.kint.2023.06.024_bib49","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1291\/hypres.29.687","article-title":"Proteinuria as a significant determinant of hypertension in a normotensive screened cohort in Okinawa, Japan","volume":"29","author":"Inoue","year":"2006","journal-title":"Hypertens Res"},{"key":"10.1016\/j.kint.2023.06.024_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.trre.2011.10.002","article-title":"Proteinuria: detection and role in native renal disease progression","volume":"26","author":"Gorriz","year":"2012","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.kint.2023.06.024_bib51","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1681\/ASN.2006040377","article-title":"How does proteinuria cause progressive renal damage?","volume":"17","author":"Abbate","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.06.024_bib52","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1093\/ndt\/gfr525","article-title":"Mouse model of proximal tubule endocytic dysfunction","volume":"26","author":"Weyer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.06.024_bib53","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1210\/me.2005-0209","article-title":"Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M","volume":"20","author":"Faber","year":"2006","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.kint.2023.06.024_bib54","doi-asserted-by":"crossref","first-page":"F988","DOI":"10.1152\/ajprenal.00295.2020","article-title":"Beyond the tubule: pathological variants of LRP2, encoding the megalin receptor, result in glomerular loss and early progressive chronic kidney disease","volume":"319","author":"Charlton","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2023.06.024_bib55","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1681\/ASN.2009040379","article-title":"Podocin inactivation in mature kidneys causes focal segmental glomerulosclerosis and nephrotic syndrome","volume":"20","author":"Mollet","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.06.024_bib56","series-title":"GeneReviews\u00ae [Internet]","article-title":"Donnai-Barrow syndrome","author":"Longoni","year":"1993"},{"key":"10.1016\/j.kint.2023.06.024_bib57","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.06.024_bib58","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41467-017-00568-7","article-title":"Heparan sulfate proteoglycans present PCSK9 to the LDL receptor","volume":"8","author":"Gustafsen","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2023.06.024_bib59","first-page":"28","article-title":"Alirocumab (Praluent): first in the new class of PCSK9 inhibitors","volume":"41","author":"Manniello","year":"2016","journal-title":"P\u00a0T"},{"key":"10.1016\/j.kint.2023.06.024_bib60","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1194\/jlr.M041129","article-title":"Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding","volume":"54","author":"Gu","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.kint.2023.06.024_bib61","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.06.024_bib62","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1074\/jbc.M808363200","article-title":"Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants","volume":"284","author":"Bottomley","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2023.06.024_bib63","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1194\/jlr.M028563","article-title":"Molecular characterization of proprotein convertase subtilisin\/kexin type 9-mediated degradation of the LDLR","volume":"53","author":"Wang","year":"2012","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.kint.2023.06.024_bib64","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2023.06.024_bib65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2008.07.106","article-title":"PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide","volume":"375","author":"Shan","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.kint.2023.06.024_bib66","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2023.06.024_bib67","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00018-012-0977-6","article-title":"PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling","volume":"69","author":"Kysenius","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.kint.2023.06.024_bib68","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.121.316902","article-title":"PCSK9 (proprotein convertase subtilisin\/kexin type 9) triggers vascular smooth muscle cell senescence and apoptosis: implication of its direct role in degenerative vascular disease","volume":"42","author":"Guo","year":"2022","journal-title":"Arterioscl Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2023.06.024_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064145","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)","volume":"8","author":"Canuel","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2023.06.024_bib70","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.bbalip.2017.05.002","article-title":"APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in\u00a0vivo","volume":"1862","author":"Fu","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.kint.2023.06.024_bib71","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00018-022-04237-x","article-title":"PCSK9 acts as a key regulator of A\u03b2 clearance across the blood-brain barrier","volume":"79","author":"Mazura","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.kint.2023.06.024_bib72","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bbrc.2008.04.004","article-title":"Secreted proprotein convertase subtilisin\/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in\u00a0vivo","volume":"370","author":"Schmidt","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.kint.2023.06.024_bib73","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1194\/jlr.M800542-JLR200","article-title":"Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice","volume":"50","author":"Luo","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.kint.2023.06.024_bib74","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7150\/ijbs.14027","article-title":"Dysregulation of the low-density lipoprotein receptor pathway is involved in lipid disorder-mediated organ injury","volume":"12","author":"Zhang","year":"2016","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.kint.2023.06.024_bib75","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1038\/s41467-018-07468-4","article-title":"Structural assembly of the megadalton-sized receptor for intestinal vitamin B12 uptake and kidney protein reabsorption","volume":"9","author":"Larsen","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2023.06.024_bib76","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1074\/jbc.273.9.5235","article-title":"The intrinsic factor-vitamin B12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins","volume":"273","author":"Moestrup","year":"1998","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2023.06.024_bib77","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1152\/physrev.00014.2021","article-title":"Albumin uptake and processing by the proximal tubule: physiological, pathological, and therapeutic implications","volume":"102","author":"Molitoris","year":"2022","journal-title":"Physiol Rev"},{"key":"10.1016\/j.kint.2023.06.024_bib78","article-title":"Vaccine against PCSK9 improved renal fibrosis by regulating fatty acid \u03b2-oxidation","volume":"9","author":"Wu","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.kint.2023.06.024_bib79","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1038\/s41598-023-31454-6","article-title":"Angiotensin II type 2 receptor activation preserves megalin in the kidney and prevents proteinuria in high salt diet fed rats","volume":"13","author":"Kulkarni","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2023.06.024_bib80","doi-asserted-by":"crossref","first-page":"18018","DOI":"10.1074\/jbc.M115.662064","article-title":"Megalin\/cubulin-lysosome-mediated albumin reabsorption is involved in the tubular cell activation of NLRP3 inflammasome and tubulointerstitial inflammation","volume":"290","author":"Liu","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2023.06.024_bib81","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/ndt\/gfu261","article-title":"Progression of renal injury toward interstitial inflammation and glomerular sclerosis is dependent on\u00a0abnormal protein filtration","volume":"30","author":"Zoja","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.06.024_bib82","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00467-004-1494-0","article-title":"Protein reabsorption in renal proximal tubule\u2014function and dysfunction in kidney pathophysiology","volume":"19","author":"Christensen","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2023.06.024_bib83","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/ki.2008.405","article-title":"Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria","volume":"74","author":"Motoyoshi","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.06.024_bib84","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1681\/ASN.2006111266","article-title":"Abrogation of protein uptake through megalin-deficient proximal tubules does not safeguard against tubulointerstitial injury","volume":"18","author":"Theilig","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823004817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823004817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:06:39Z","timestamp":1758762399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253823004817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0085253823004817"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2023.06.024","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proprotein convertase subtilisin\/kexin type 9 targets megalin in the kidney proximal tubule and aggravates proteinuria in nephrotic syndrome","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2023.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}